Literature DB >> 18777213

Treatment of malignant ascites.

Michael Chung1, Peter Kozuch.   

Abstract

OPINION STATEMENT: The management of malignant ascites is a significant challenge in gastrointestinal medical oncology. Current treatment strategies include diuretic therapy, paracentesis, peritoneal drains, and venous shunts. However, there are no established evidence-based guidelines, and there is a lack of randomized controlled trials identifying optimal therapy. Newer therapies are emerging and will need further study. By summarizing published studies, this review is intended to add some clarity to currently available strategies for the management of malignant ascites associated with hepatobiliary cancers. Notably, however, much of the available data for the management of malignant ascites comes from the gynecologic oncology experience, specifically from studies in ovarian cancer. Therefore, successful approaches used in this malignancy may be lead candidates for development in hepatobiliary cancer-associated ascites and are reviewed in this paper.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18777213     DOI: 10.1007/s11864-008-0068-y

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  74 in total

1.  Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites.

Authors:  A Garofalo; M Valle; J Garcia; P H Sugarbaker
Journal:  Eur J Surg Oncol       Date:  2006-04-21       Impact factor: 4.424

Review 2.  Malignant ascites: systematic review and guideline for treatment.

Authors:  Gerhild Becker; Daniel Galandi; Hubert E Blum
Journal:  Eur J Cancer       Date:  2006-01-24       Impact factor: 9.162

3.  Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites.

Authors:  S L Parsons; S A Watson; R J Steele
Journal:  Eur J Surg Oncol       Date:  1997-12       Impact factor: 4.424

4.  The successful treatment of chylous effusions in malignant disease with octreotide.

Authors:  L Mincher; J Evans; M W Jenner; V A Varney
Journal:  Clin Oncol (R Coll Radiol)       Date:  2005-04       Impact factor: 4.126

Review 5.  The current and future management of malignant ascites.

Authors:  E M Smith; G C Jayson
Journal:  Clin Oncol (R Coll Radiol)       Date:  2003-04       Impact factor: 4.126

6.  Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study.

Authors:  S Sartori; I Nielsen; D Tassinari; L Trevisani; V Abbasciano; P Malacarne
Journal:  Oncology       Date:  2001       Impact factor: 2.935

7.  Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo.

Authors:  A Yukita; M Asano; T Okamoto; S Mizutani; H Suzuki
Journal:  Anticancer Res       Date:  2000 Jan-Feb       Impact factor: 2.480

8.  Malignant ascites: demographics, therapeutic efficacy and predictors of survival.

Authors:  J R Mackey; P M Venner
Journal:  Can J Oncol       Date:  1996-11

9.  Peritoneovenous shunts for palliation of the patient with malignant ascites.

Authors:  D L Schumacher; T J Saclarides; E D Staren
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

10.  Control of malignant ascites by peritoneovenous shunting.

Authors:  I R Gough
Journal:  Cancer       Date:  1984-11-15       Impact factor: 6.860

View more
  22 in total

1.  Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.

Authors:  Klaus Pietzner; Ignace Vergote; Armando Santoro; Radoslav Chekerov; Frederik Marmé; Per Rosenberg; Holger Martinius; Hilke Friccius-Quecke; Jalid Sehouli
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

2.  Oxidative dna damage of lymphocytes in peripheral blood and ascites in cancer patients.

Authors:  J Wang; S S Xing; S B Guo; W Jin; W Zhang
Journal:  Curr Oncol       Date:  2012-07       Impact factor: 3.677

3.  84-year-old man with respiratory distress and abdominal distention.

Authors:  Deirdre R Pachman; Thomas B Morrison; Jason H Szostek
Journal:  Mayo Clin Proc       Date:  2011-02       Impact factor: 7.616

4.  Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer.

Authors:  Diana L Moughon; Huanhuan He; Shiruyeh Schokrpur; Ziyue Karen Jiang; Madeeha Yaqoob; John David; Crystal Lin; M Luisa Iruela-Arispe; Oliver Dorigo; Lily Wu
Journal:  Cancer Res       Date:  2015-10-15       Impact factor: 12.701

5.  Differential expression of vascular endothelial growth factor-A, -C and -D for the diagnosis and prognosis of cancer patients with malignant effusions.

Authors:  Lin Jia; Yun DU; Tao Li; Yalei Lv; Yudong Wang; Yan Zhang; Xinliang Zhou; Wei Liu
Journal:  Oncol Lett       Date:  2015-06-02       Impact factor: 2.967

6.  Safety of repeated cell-free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer.

Authors:  Osamu Maeda; Takafumi Ando; Kazuhiro Ishiguro; Osamu Watanabe; Ryoji Miyahara; Masanao Nakamura; Kohei Funasaka; Furukawa Kazuhiro; Yuichi Ando; Hidemi Goto
Journal:  Mol Clin Oncol       Date:  2014-07-04

7.  Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites.

Authors:  Hongmei Wei; Shukui Qin; Xiaojin Yin; Yali Chen; Haiqing Hua; Lin Wang; Ningrong Yang; Yingxia Chen; Xiufeng Liu
Journal:  Oncol Lett       Date:  2015-04-21       Impact factor: 2.967

8.  Palliative treatment of malignant ascites: profile of catumaxomab.

Authors:  Lila Ammouri; Eric E Prommer
Journal:  Biologics       Date:  2010-05-25

Review 9.  Colorectal cancer emergencies.

Authors:  Andy Barnett; Anna Cedar; Faisal Siddiqui; Daniel Herzig; Emilie Fowlkes; Charles R Thomas
Journal:  J Gastrointest Cancer       Date:  2013-06

Review 10.  Management of drainage for malignant ascites in gynaecological cancer.

Authors:  Alison Keen; Debbie Fitzgerald; Andrew Bryant; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.